Transpupillary thermotherapy (TTT) photocoagulation is a method of delivering heat to
the back of the patient's eye using an 810 nm infrared laser (IRIS Medical OcuLight SLx). This creates a localized hyperthermia, a natural healing mechanism, which results in closure
of choroidal vessels. TTT is commonly used worldwide as an effective treatment for ocular tumors such as retinoblastoma and choroidal melanoma. Preliminary results of TTT treatment
in subfoveal occult choroidal neovascularization (CNV) in age-related macular degeneration (AMD), have shown to reduce subretinal fluid in about 90% of cases and stabilize or improve
vision in about 75% of cases without the substantial side effects of laser photocoagulation performed at conventional settings.
The study titled "Transpupillary Thermotherapy
(TTT) Of Occult Subfoveal Choroidal Neovascular Membranes (CNV) In Patients With Age-Related Macular Degeneration" (shortened to TTT4CNV) is a prospective, randomized,
sham-controlled, multi-center clinical trial intended to ultimately determine the effectiveness of TTT in the treatment of occult CNV caused by AMD when compared to no treatment.
If you have occult wet AMD and would like to be considered for patient enrollment in the TTT4CNV clinical trial, please review the following eligibility requirements with your retina
specialist to determine if you meet them. If so, contact the study coordinator at the study center closest to you.
